Day One Biopharmaceuticals, Inc.
DAWN
$21.31
$0.020.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.72M | 39.80M | 33.91M | 30.76M | 29.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.72M | 39.80M | 33.91M | 30.76M | 29.21M |
| Cost of Revenue | 6.08M | 4.48M | 3.77M | 2.88M | 2.98M |
| Gross Profit | 47.64M | 35.32M | 30.14M | 27.88M | 26.23M |
| SG&A Expenses | 34.15M | 28.15M | 28.97M | 29.33M | 29.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.18M | 64.05M | 68.88M | 71.83M | 94.54M |
| Operating Income | -27.46M | -24.25M | -34.97M | -41.07M | -65.33M |
| Income Before Tax | -23.25M | -19.73M | -30.32M | -36.00M | -59.24M |
| Income Tax Expenses | -1.98M | -- | -- | -- | 6.47M |
| Earnings from Continuing Operations | -21.28M | -19.73M | -30.32M | -36.00M | -65.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.28M | -19.73M | -30.32M | -36.00M | -65.71M |
| EBIT | -27.46M | -24.25M | -34.97M | -41.07M | -65.33M |
| EBITDA | -26.57M | -23.37M | -34.09M | -40.25M | -64.71M |
| EPS Basic | -0.19 | -0.19 | -0.29 | -0.35 | -0.64 |
| Normalized Basic EPS | -- | -0.12 | -0.18 | -0.22 | -0.36 |
| EPS Diluted | -0.19 | -0.19 | -0.29 | -0.35 | -0.64 |
| Normalized Diluted EPS | -- | -0.12 | -0.18 | -0.22 | -0.36 |
| Average Basic Shares Outstanding | -- | 103.38M | 103.07M | 102.71M | 102.44M |
| Average Diluted Shares Outstanding | 103.38M | 103.38M | 103.07M | 102.71M | 102.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |